277 related articles for article (PubMed ID: 31487998)
1. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis.
Crespo C; Linhart M; Acosta J; Soto-Iglesias D; Martínez M; Jáuregui B; Mira Á; Restovic G; Sagarra J; Auricchio A; Fahn B; Boltyenkov A; Lasalvia L; Sampietro-Colom L; Berruezo A
Eur J Prev Cardiol; 2020 Apr; 27(6):622-632. PubMed ID: 31487998
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change.
Claridge S; Sebag FA; Fearn S; Behar JM; Porter B; Jackson T; Sieniewicz B; Gould J; Webb J; Chen Z; O'Neill M; Gill J; Leclercq C; Rinaldi CA
Heart; 2018 Mar; 104(5):416-422. PubMed ID: 28970277
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
[TBL] [Abstract][Full Text] [Related]
4. Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure.
Elsner C; Bettin S; Tilz R; Häckl D
Curr Heart Fail Rep; 2024 Jun; 21(3):186-193. PubMed ID: 38662154
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
7. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
8. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry.
Behar JM; Chin HM; Fearn S; Ormerod JO; Gamble J; Foley PW; Bostock J; Claridge S; Jackson T; Sohal M; Antoniadis AP; Razavi R; Betts TR; Herring N; Rinaldi CA
JACC Clin Electrophysiol; 2017 Feb; 3(2):107-116. PubMed ID: 28280785
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial.
Wilkoff BL; Boriani G; Mittal S; Poole JE; Kennergren C; Corey GR; Krahn AD; Schloss EJ; Gallastegui JL; Pickett RA; Evonich RF; Roark SF; Sorrentino DM; Sholevar DP; Cronin EM; Berman BJ; Riggio DW; Khan HH; Silver MT; Collier J; Eldadah Z; Holbrook R; Lande JD; Lexcen DR; Seshadri S; Tarakji KG
Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008503. PubMed ID: 32915063
[TBL] [Abstract][Full Text] [Related]
12. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.
Tomini F; Prinzen F; van Asselt AD
Eur J Health Econ; 2016 Dec; 17(9):1159-1172. PubMed ID: 26728985
[TBL] [Abstract][Full Text] [Related]
13. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.
Landolina M; Morani G; Curnis A; Vado A; D'Onofrio A; Bianchi V; Stabile G; Crosato M; Petracci B; Ceriotti C; Bontempi L; Morosato M; Ballari GP; Gasparini M
Europace; 2017 Aug; 19(8):1349-1356. PubMed ID: 27702861
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.
Nichols CI; Vose JG; Mittal S
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873688
[TBL] [Abstract][Full Text] [Related]
16. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia.
Atehortúa S; Senior JM; Castro P; Ceballos M; Saldarriaga C; Giraldo N; Mora G
Biomedica; 2019 Sep; 39(3):502-512. PubMed ID: 31584764
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
Shah D; Lu X; Paly VF; Tsintzos SI; May DM
J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
[No Abstract] [Full Text] [Related]
19. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.
Aidelsburger P; Grabein K; Klauss V; Wasem J
Clin Res Cardiol; 2008 Feb; 97(2):89-97. PubMed ID: 17955159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
